Objective: Data from the National Taiwan Cancer Registry have been widely used since 2002 to assess quality of health, but its quality of coding in cancer staging data has not been discussed. This study assessed the agreement rate for staging by site visit at medical institutes. Methods: In this retrospective chart review study, 392 cancer patients in year 2013 were randomly selected from 14 hospitals; the senior cancer registrar reviewers had compared each original chart with data from the Taiwan Cancer Registry to assess agreement rate for staging. The hospitals were classified into two groups on the basis of the number of cancer patients. The kappa (κ) statistic method and multiple regression analysis were used to compare among the medical institutes and qualified cancer registrars. Results: The agreement rate was high in pharynx, esophageal, rectal, breast and prostate cancers, and low in ovarian and other cancers for clinical and pathological staging. After adjustment for the experience of the qualified cancer registrar, low-caseload hospitals had a significantly lower clinical staging agreement rate than that of high-caseload hospitals. After controlling the hospital cancer caseloads the cancer registrar background becomes one of significant factor. That is long duration between a basic license to an advanced license exceeded 5 years, having lower agreement rate. Conclusions: The reliability of staging data in the Taiwan Cancer Registry is affected not only by the cancer type but also by the number of patients treated in hospital. Moreover, the experience of cancer registrar strongly influences agreement rate, especially in clinical staging.
Introduction
Cancer, a leading cause of mortality worldwide, accounted for >8 million cancer-related deaths in 2012 (1) ; similarly, cancer has been the leading cause of mortality in Taiwan since 1982. The Taiwan Cancer Registry (TCR), established in 1979, was the first such registry established in Asia (2) .
With improvement in the diagnosis and treatment of cancer patients, the scope of TCR data collection has also increased and has included data on cancer staging, first course of treatment, and cancer-related factors since the early 2000s. Therefore, these data are used for monitoring the long-term trends, prevalence and incidence of cancer as well as the indicators used in healthcare evaluation. TCR data has also been used as a resource for cancer-related research in several studies on the uniqueness of the TCR database or other related databases, such as the National Health Insurance Research Database, clinical laboratory test results database and National Register of Deaths (3) (4) (5) (6) (7) . Cancer databases in Taiwan are widely used and are rapidly growing. Consequently, the validity of these databases and records is a major concern.
Studies on the validity of cancer registry data have been published since the early 1900s. By comparing the discharge data of one hospital with the tumour registry data, Kahn et al. (8) demonstrated that discharge data might not be a reliable source for data on the clinical staging. Harvei et al. (9) selected prostate cancer patients from eight hospitals and demonstrated that inaccurate coding of 'metastasis' accounted for~50% of the minor errors. Brewster et al. (10) compared Cancer Registry with the medical records and concluded that the registry was relatively less reliable source for data on the clinical staging. Errors in tumour staging are caused by poor medical record documentation, which in turn resulted in accurate data collection (11, 12) . Jensen et al. (13) demonstrated a high disagreement rate between tumour staging data and those in the clinical information, particularly, for the metastasis of bilateral breast cancer. Malin et al. (14) reported that Cancer Registry provided highly accurate hospital data and that it exhibited a moderate agreement for staging.
From 45 randomly selected hospitals, You et al. (15) obtained copies of medical records for abstraction and demonstrated that the quality of the registry data in terms of their validity was considerably lower on the histological proof than on patient identification. Wu et al. (16) indicated that according to a medical centre for colorectal cancer, the agreement of re-abstraction in the stages of primary tumour location was low.
Most studies have demonstrated that the agreement for tumour staging was low and that data for determining the clinical and pathological stages was lacking. A population-based descriptive study was conducted in the 1990s in Taiwan, but data on tumour staging were not collected at that time. Wu et al. demonstrated that the accuracy of tumour stages was low, but the authors could not extrapolate the findings to represent the entire population because the study was limited to a single cancer centre. No studies have yet assessed the quality of staging in Taiwan; therefore, this study compared the agreement rate for clinical and pathological staging between the original chart records and the TCR to determine the influence of the nature of medical institute and the experience of cancer registrars on staging data agreement.
Patients and Methods

Cancer registry
The National Cancer Registry system was founded in 1979 and covers >97% of the population of Taiwan (17) . The data quality control indicators meet the IARC guidelines on completeness, and the accuracy of registration in terms of death certification only was 0.86% and that for morphologically verified cases (MV%) was 91.0% in 2010 (18) .
The data collection procedures must be continually enhanced to ensure data quality in the TCR. These procedures include legislation, manpower and processes. Regarding legislation, all healthcare facilities with >50 beds must submit their data before the deadline under the Cancer Prevention Act of 2003. Regarding manpower, all healthcare facilities must hire a qualified or trained cancer registrar for cancer registration. Regarding processes, all hospitals must satisfy the logic checks online before submitting the data to the national registry. Moreover, they must review and confirm the medical records again when the logic checks detect a coding error. The registrars must correct the data first before submitting them. Therefore, it is reasonable to assume that the data are error-free when they arrive at the TCR. However, when the logic checks detect a coding error, the registrars verify the data again, and must provide all the documentation required to support the judgment. These cases are referred to as 'return questionable data' when the reporting data is assessed by the TCR, and the Health Promotion Administration records the rate of disagreement between TCR data and the original medical chart data from hospitals as an indicator of quality of cancer care.
Study population-Case identification and sampling
We selected 14 hospitals from 81 hospitals in which 2% of data were returned as questionable from 1 January to 31 December 2013 according to the long-form data from TCR. The level of returned questionable data was the criteria used for selection of hospitals. Twenty-eight records were randomly selected from each of the 14 selected hospitals, resulting in a total of 392 medical records that were then reabstracted for this study, including the head and neck, oesophagus, stomach, colorectal, liver, lung, breast, female genital system, prostate and bladder cancer and haematopoietic diseases.
The tumour stages were divided into clinical and pathological groups according to the guidelines of the American Joint Committee on Cancer (AJCC). The database was classified into two caseload categories according to the total cases reported by the healthcare facilities in 2013. The facilities reporting >800 cases were classified as high-caseload facilities, and the remaining were classified as lowcaseload facilities.
Treatments were categorized into three groups: no treatment, surgery and chemotherapy or radiotherapy. The tumour location groups were the high agreement rate group (e.g. Clinical Stage included Head and Neck, Respiratory System, Breast, Prostate and Female Genital System Cancers; Pathological Stage included Head and Neck, Digestive System, Breast, Prostate, Bladder and Hematopoietic Diseases) and the low agreement rate group (e.g. Clinical Stage included Digestive System, Bladder, Hematopoietic Diseases and Other Cancers; Pathological Stage included Respiratory System, Female Genital System and Other Cancers).
Hospitals were classified according to their location into four groups: north, center, south and east. Cancer registrars who submitted staging data to the TCR were classified into two groups according to the volume of submitted cancer data during 2012-14. Registrars who submitted data on >1100 cases were classified as high-volume registrars, whereas the others were classified as lowvolume registrars. In addition, qualified cancer registrars were grouped according to the time taken by the registrars to graduate from a basic license to an advanced license as long duration (>5 years) and short duration (<5 years).
Chart review
This study compared the medical charts and TCR database using reabstractors on clinical and pathological stages; the reabstracted items included cancer identification, tumour stage and first course of treatment. Seven personnel, including one clinician and six reviewers, senior certified cancer registrars, were provided the preliminary training before visiting the selected hospitals. All the reabstracted items adhered to the form that was confirmed by the personnel committee of cancer care, and a senior cancer registrar reabstracted all 392 medical records.
Any observed disagreement was resolved through discussions between the reabstractors and subsequently classified as a disagreement. However, if the difference was not recognized by the original registrars, the suspected cases were reconfirmed and a final decision was made after meeting with the personnel committee of cancer care. The total number of such cases was very small (<1%).
The reabstractors wrote the accurate code when an erroneous code was determined, after discussion with the original registrars, as stated earlier. This process was repeated until all medical charts were reabstracted. We established the codes based on ICD-O-3 for all sites and morphology (19, 20) , and all cancer staging was performed according to the seventh edition of the AJCC guidelines (21) .
We measured the rates of agreement between the abstractors for individual variables by using the inter-rater reliability method. The senior cancer registrar reviewers had to compare each original chart with the data from the TCR to assess the agreement rate for staging. An on-site reviewing process of 392 medical charts was conducted, and the chart data were used as the standard.
Statistical analysis
The rates of agreement between the reabstractors and original registrars were calculated according to data in the tumour registry and medical charts. The agreement rate and kappa statistic (κ) were used to operationalize the agreement level.
Landis and Koch (22) reported that a kappa value of 0-0.20 indicated a poor agreement between databases, 0.21-0.40 indicated a fair agreement, 0.41-0.60 indicated a moderate agreement, 0.61-0.80 indicated a substantial agreement and 0.81-1.0 indicated a near perfect agreement (23) .
This study investigated the agreement rate for clinical and pathological staging data between the TCR and original chart records. Multivariate logistic regression with 95% confidence intervals (95% CIs) was used to estimate the effect of hospital cancer volume, hospital location, volume of cancer data submitted to the TCR by the registrars during 2012-14 and time interval for registrars to graduate from a basic to an advance license agreement on tumour staging data in the TCR and medical charts, as is the case in the literature (24) (25) (26) (27) . All analyses and reporting procedures were performed using SAS 9.3 software. Table 1 presents the agreement rate between TCR data and original chart record for 2013. The agreement rate for both clinical and pathological staging was the highest in young patients (age ≤49 years) and lowest rate in patients without treatment. Agreement rate for clinical staging was the lowest both in low-caseload hospitals and among registrars who took >5 years to graduate from a basic to an advanced license. Table 2 shows the agreement rate by cancer type. For pathological staging, the agreement rate was lowest in lung cancer and highest in gastrointestinal cancer. For clinical staging, the agreement rate was lowest in hematologic cancer and highest in head and neck cancer. After re-abstracting the cancer registration data, the agreement rate for pathological staging (κ = 0.898; 95% CI 0.855-0.941) was higher than that for clinical staging (κ = 0.743; 95% CI 0.651-0.835). In general, excellent agreement was observed for pathological staging and substantial agreement for clinical staging.
Results
As shown in Table 3 , after adjustment for the experience of qualified cancer registrars, the agreement rate for clinical and pathological staging was significantly higher in high-caseload hospitals (3.48-fold and 2.19-fold, respectively). The agreement rate for pathological staging was significantly lower for hospitals in the central Taiwan compared with those in the other regions. After adjustment for cancer caseload and hospital location, the agreement rate for pathological staging was nonsignificantly lower for qualified basic license registrars who took >5 years to acquire an advanced license. However, the corresponding agreement rate for clinical staging was significantly lower.
Discussion
Our data are collected from 14 hospitals, an average rate of >2% of return questionable data for reconfirmation, which indicates relatively disagreement between clinical stage and pathological stage data. The quality of coding could be better if we just simply sampling randomly from all hospitals. Our results show that the staging consistency is lower than treatment misregistration in both clinical and pathological stages, which is consistent with results of other studies (10, 13, 16, 28) .
A near-perfect agreement was observed between the two databases for the pathological stage, and the high agreement rate was similar to that in some studies (28, 29) but was higher than that in most studies (8, 10, 14, 16, (30) (31) (32) . Several possible reasons may exist for this result. First, the tumour stage was classified into two groups. Second, the data quality indicators of proportion for MV% increased to 91.3% in 2011 in Taiwan (2). Third, the pathology report, which contains variables for cancer staging, fulfilled AJCC TNM staging in 2008. Pathologists strictly follow these guidelines since 2008, and the hospital performance on these measures is evaluated during cancer recognition in Taiwan (33, 34) .
For clinical stage, the results show a high agreement (>90%) of tumour registry data, we also discovered that our results were higher than those of other studies (10, 30) . Three possible reasons might explain the agreement rate of the clinical stage. First, previous studies were performed in the past 10 years. Second, the radiologists had to follow the guidelines that contained variables for cancer staging to meet the AJCC, which was developed in Taiwan since 2010. In Others included Parotid gland (n = 1), Small intestine (n = 2), Anus (n = 1), Intrahepatic bile duct (n = 3), mediastinum (n = 1), Pleura (n = 1).
addition, the completeness of a radiology report of CT (computed tomography) and magnetic resonance imaging (MRI) was an element for the national quality improvement programme in Taiwan. Finally, this study was performed according to the gold standard of chart documentation, and the entire medical record data were reviewed to determine the disagreement by reabstractors to meet the original registrars (33) (34) (35) . For pathological staging, the lowest agreement rate was found in oral, lung and ovarian cancers, probably because head and neck cancers, which includes cancer at several subsites, was analyzed as a single entity. Moreover, the employed imaging technique (e.g. CT and MRI) played a major role in staging and treatment (36) . Registrars who incorrectly interpreted the metastasis sites in pathology reports caused the most errors. Additional analyses revealed that such erroneous cases were concentrated in cytology-proven Stage IV lung cancer. The agreement rate for ovarian cancer was lower in the group. This may because data on ovarian cancer staging has been recorded in the TCR only since 2010; hence, consensus on appropriate medical documentation and checklists for image-based and pathological reporting is lacking.
Gastrointestinal cancers (stomach, colon and liver cancers), especially at the early stage, had the lowest agreement rate for clinical staging, followed by bladder cancer. The following three reasons may explain this disagreement: limitations associated with staging through CT, MRI or clinical experience; poor medical documentation (11, 12, 30) ; lack of strong cancer staging skills among registrars. In bladder cancer, possible causes for the low agreement are poor or missing staging assessment and the use of transurethral resection of bladder tumor (TURBT) for staging (e.g. the depth of invasion) or as the first-line surgery for non muscular invasive tumour. Nevertheless, pathological proof is crucial in diagnosis and staging, and this study exhibited the highest agreement rate in pathological staging.
High-caseload hospitals had high agreement for both clinical and pathological stage. After adjustment for the experience of qualified cancer registrars, the agreement rate for clinical staging in highcaseload hospitals was 3.5-fold higher than that in low-caseload hospitals. The lowest agreement rate for clinical staging was observed in early-stage cancers in low-caseload hospitals, possibly because of the following reasons. First, diagnoses of early stage cancers require either clinical experience or advanced imaging. However, low-caseload hospitals might not have such facilities, and they receive very less reimbursement from the National Health Insurance Administration. Moreover, for pathological staging, the lowest agreement rate occurred at an 'unknown' stage lung cancer. In addition, cytologically proven Stage IV cases were being miscoded, because hospitals employ only one qualified cancer registrar despite thousands of new cancer diagnoses, these registrars cannot adequately perform peer review, quality auditing and monitoring on all diagnoses (35) .
Furthermore, the agreement rates for pathological stage in all advanced cancers were significantly lower in hospitals located in central Taiwan and in low-caseload hospitals, possibly because clinicians documented only prognosis and treatment but not other information such as CT/MRI findings and pathological microscopy findings. Registrars may still face problems in acquiring the appropriate information.
The agreement rate for clinical staging was low if the time needed for registrars to graduate from a basic license to an advanced license exceeded 5 years (Table 3 ). Additional analyses revealed that the main reason for low agreement for clinical staging was errors in coding as a specific stage, which mostly occurred in stomach, liver and colorectal cancers; this can be attributed to several reasons. First, clinical staging requires objective imaging reports, which the registrars interpret based on the guidelines of the TCR coding manual; the registrars may lack the adequate judgment necessary to identify the appropriate cancer stage. Second, patients with advanced or complex stages are usually referred from another facility, and the available information provided might be limited, leading to potential miscoding by the registrars. Upcoding in the bladder cancer group was a reason for its low agreement rate. This might be because (i) staging through TURBT is difficult when diagnosing early-stage cancers and thus the TCR coding manual guidelines were revised in 2012 and (ii) Data on bladder cancer staging was initiated only after 2010, and the registrars therefore need more time to acquaint themselves with the data (20) . We also found that the agreement rate increased over time in clinical and pathological stages after 2010 for the starting year of stage collection. In Taiwan, many improvement methods have been used, for example, the chest CT and MRI and pathology reports were established uniformly according to the different types of cancer, and the specialists followed these guidelines and recorded their findings in radiology and pathology reports since 2008 (33, 34) .
This study has several limitations. First, the study results may not be applicable to all the hospitals in Taiwan, and they are restricted to patients diagnosed with common cancers. Therefore, the validity of the cancer registry data on stages in rare cancers is unknown. Second, these cancer patients have been identified only from the TCR data, and the accuracy of cancer stages for non-TCR cases is unknown. Third, the cross-sectional study cannot validate the stages for every cancer yet, because the study did not include sufficient cases for each cancer. Longitudinal research can provide data over the years or even decades, and investigators should include sample cases to validate the stages for each cancer case in the future. Finally, disagreement staging data in the TCR arise through not only registrar errors but also inappropriate medical recordkeeping. However, the impact of errors that arise from inappropriate medical recordkeeping is unknown and warrants further investigation.
In summary, TCR is a reliable data registry for cancer staging; however, the quality of cancer staging data, especially clinical staging, in the TCR depends not only on the cancer type but also on the hospital caseload and the experience of cancer registrars. Therefore, low-caseload medical institutes and routine verification by external experts should be focused on. Furthermore, cancer registrars with basic licenses must be trained to obtain advanced licenses. The collecting high-quality data is a critical part of continuous training, promoting structured report and ensuring high standards of medical recording.
